Open-label Nexagon® (lufepirsen)

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular InjuriesNCT04081103Glaukos CorporationPhase 2Terminated2022-02-07Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.